Oncotarget, Vol. 7, No. 4

www.impactjournals.com/oncotarget/

Identification of H7 as a novel peroxiredoxin I inhibitor to
induce differentiation of leukemia cells
Wei Wei1,*, Chunmin Ma1,*, Yang Cao1,*, Li Yang1,*, Zhimin Huang1,*, Dongjun Qin1,
Yingyi Chen1, Chuanxu Liu2, Li Xia1, Tongdan Wang1, Hu Lei1, Yun Yu1, Min Huang1,
Yin Tong4, Hanzhang Xu1, Fenghou Gao3, Jian Zhang1,*, Ying-Li Wu1,*
1

 ongqiao International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Chemical Biology
H
Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of The Chinese Ministry
of Education, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

2

Department of Hematology, Xinhua Hospital Shanghai Jiao-Tong University School of Medicine, Shanghai, 200092, China

3

I nstitute of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011,
China

4

 epartment of Hematology, Shanghai First People's Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai,
D
200081, China

*

These authors contributed equally to this work

Correspondence to: Ying-Li Wu, e-mail: wuyingli@shsmu.edu.cn
Jian Zhang, e-mail: jian.zhang@sjtu.edu.cn

Keywords: peroxiredoxin, leukemia, cell differentiation, reactive oxygen species
Received: June 09, 2015	

Accepted: November 28, 2015	

Published: December 26, 2015

ABSTRACT
Identifying novel targets to enhance leukemia-cell differentiation is an urgent
requirment. We have recently proposed that inhibiting the antioxidant enzyme
peroxiredoxin I (Prdx I) may induce leukemia-cell differentiation. However, this
concept remains to be confirmed. In this work, we identified H7 as a novel Prdx
I inhibitor through virtual screening, in vitro activity assay, and surface plasmon
resonance assay. Cellular thermal shift assay showed that H7 directly bound to Prdx
I but not to Prdxs II–V in cells. H7 treatment also increased reactive oxygen species
(ROS) level and cell differentiation in leukemia cells, as reflected by the upregulation
of the cell surface differentiation marker CD11b/CD14 and the morphological
maturation of cells. The differentiation-induction effect of H7 was further observed in
some non-acute promyelocytic leukemia (APL) and primary leukemia cells apart from
APL NB4 cells. Moreover, the ROS scavenger N-acetyl cysteine significantly reversed
the H7-induced cell differentiation. We demonstrated as well that H7-induced cell
differentiation was associated with the activation of the ROS-Erk1/2-C/EBPβ axis.
Finally, we showed H7 treatment induced cell differentiation in an APL mouse model.
All of these data confirmed that Prdx I was novel target for inducing leukemia-cell
differentiation and that H7 was a novel lead compound for optimizing Prdx I inhibition.

INTRODUCTION

agents, such as vitamin D and 1, 25-dihydroxy vitamin
D3 [2–4], differentiation therapy failed in most non-APL
leukemia cases. Therefore, a deep understanding of the
molecular mechanisms of leukemia cell differentiation, as
well as identifying novel differentiation agents, is urgently
required.
In the mammalian hematopoietic system, the reactive
oxygen species (ROS) levels are apparently important in
controlling myeloid precursor differentiation. Accumulating
data have shown that ROS-modulating agents, such as

In acute myeloid leukemia (AML), immature
cells are blocked abnormally at an early stage of their
development and fail to differentiate into functional
mature cells. The introduction of all trans-retinoic acid
into the acute promyelocytic leukemia (APL) therapy
validated the concept of differentiation therapy [1].
However, differentiation therapy remains limited to APL
treatment. Despite the discovery of many differentiation
www.impactjournals.com/oncotarget

3873

Oncotarget

arsenic trioxide, DFO, and tetrandrine, may regulate
leukemia differentiation by increasing ROS levels [5–10].
Therefore, identification of small molecules exhibiting
ROS-modulating activity may provide new tool in
investigating the underlying mechanisms of leukemia-cell
differentiation and in developing new therapy for leukemia.
Peroxiredoxins (Prdxs) are a superfamily of small
non-selenoperoxidases that contain essential catalytic
cysteine residues and use thioredoxin as an electron donor
in reducing hydrogen peroxide (H2O2) [11]. At least six
mammalian isoforms, including two-cysteine (Prdxs I–IV),
atypical two-cysteine (Prdx V), and one-cysteine
(Prdx VI) Prdxs have been identified [12–13]. Prdx I
is abundant in cells, constituting a total of 0.2%–1%
of soluble protein in cultured mammalian cells [14].
Emerging data have shown that Prdx I levels are elevated
in several human cancer cells and tissues, such as oral,
esophageal, pancreatic, follicular thyroid, breast, and
lung cancers. The elevated Prdx I proteins enhance the
aggressive survival phenotype of cancer cells and confer
an increased resistance to chemotherapy and radiotherapy
[15–19]. We recently demonstrated that adenanthin,
a natural diterpenoid, could induce differentiation of
leukemia cells through the Prdx I/ROS axis [20–21].
We then proposed that Prdx I represents a novel target in

developing differentiation agents. However, this concept
need to be further confirmed.
Using virtual screening, along with in vitro and
cellular assay, we identified in this study that H7 is a
novel Prdx I inhibitor. We further demonstrated that H7
induces leukemia-cell differentiation in vitro and in vivo.
We validate the notion that Prdx I is a novel target that
induces leukemia-cell differentiation and H7 is a novel
lead compound for developing Prdx I inhibitors.

RESULTS
H7 is a novel Prdx I inhibitor
We used virtual screening, along with in vitro Prdx
I activity assay, to identify the novel Prdx I inhibitors.
In the virtual screening, the candidate compounds from
different scaffolds were selected and their potency for
Prdx I inhibition was analyzed using the in vitro Prdx I
activity assay. Among the compounds, H7 (Figure  1A)
showed the most potent inhibition of Prdx I activity and
was thus selected for further investigation. The IC50 of H7
on Prdx I activity was 7.85 μM (Figure 1B). Moreover,
docking study showed that H7 is buried in a pocket
composed of Leu46, Phe48, Phe50, Val51, Cys52, Lys120,

Figure 1: H7 inhibits Prdx I catalytic activity. (A) Chemical structure of H7. (B) The recombinant Prdx I protein was incubated with
the indicated concentration of H7 for 1 h, and its peroxidase activity was monitored for 1200 s. The IC50 of H7 on Prdx I was calculated
by the Graphpad prism software. All values represent the means ± S.D. of three independent experiments. (C) Binding model of H7 and
Prdx I. The molecular surface of Prdx I protein is shown in gray and the H7 molecule is shown as sticks with light blue carbons. (D) SPR
analysis of the binding between Prdx I and H7. The recombinant Prdx I protein was immobilized on an activated CM5 chip. H7 was then
flowed across the chip at increasing concentrations. The chip was regenerated between concentrations using 2 M glycine. Dose-dependent
binding of H7 was observed across the concentration range.
www.impactjournals.com/oncotarget

3874

Oncotarget

Ile125, Arg128, and Asp146. Moreover, The sulfonyl and
carbonyl group of H7 form four hydrogen bonds, of which
make it to stably interact with and inhibit Prdx I, with both
side chains of Lys120, Arg128, Asp146 and main chain of
Val51, respectively (Figure 1C). These data suggest that
H7 is a novel Prdx I inhibitor.
The binding between H7 and Prdx I was further
evaluated by surface plasmon resonance (SPR) assay
using a biacore platform. The sensorgrams showed that H7
rapidly associated and disassociated from the immobilized
Prdx I at a dissociation constant of 1.57 μM (Figure 1D).
Moreover, the response signal during the dissociation
phase returned to the baseline level for H7, indicating
complete dissociation of the compound from Prdx I. These
data suggest that H7 is non-covalently bound to Prdx I.

is based on the concept that the direct binding of a small
molecule to its target protein may increase the stability
of proteins in response to heat [22]. Figure  2A and 2B
showed that the addition of H7 but not DMSO into the
cell lysates increased the stability of Prdx I at different
temperatures. Prdx I was highly stabilized at 75.9°C.
However, H7 did not significantly affect the stability of
Prdxs II–V, indicating the relative selectivity of H7 on
Prdx I (Figure 2C). Moreover, the stabilization effect of
H7 on Prdx I is dose dependent (Figure 2D). Given that
Prdx I functions as a H2O2 scavenger, we subsequently
determined whether H7 treatment increases ROS level
in NB4 cells. The ROS level in the H7-treated NB4 cells
gradually increased, peaked after 12 h, and then declined
after 24 h (Figure 4E). These data demonstrate that H7
could reach its target protein Prdx I in a biologically
relevant setting, leading to increased ROS level.

H7 interacts with Prdx I in cells
To investigate whether the interaction between
H7 and Prdx I observed in vitro does occur in cells, we
performed cellular thermal shift assay (CETSA). CETSA
is a newly developed method of measuring the direct
binding of protein with its ligand in cells; this technique

H7 induces NB4 cell differentiation
Given that targeting Prdx I by adenanthin induces
leukemia-cell differentiation [20], we then determined
whether H7 can also induce leukemia-cell differentiation. H7

Figure 2: H7 interacts with Prdx1 in cells. (A) The NB4 cell lysate was incubated with DMSO or H7 at different temperatures for

3 min followed by centrifugation at 20 000 g. The supernatant was subjected to Western blot analysis of the Prdxs I–V proteins. (B–C) The
intensity of the bands of the Prdxs I–V proteins were quantified by the Quantity One software, and the relative ratio of H7- and DMSOtreated bands (H / D) was displayed. All values represent the means ± S.D. of three independent experiments. *p < 0.05. Prdx IV was used
as a loading control. (D) The NB4 cell lysate was incubated with DMSO or different H7 concentrations at 75.9°C for 3 min followed by
centrifugation at 20,000 g. The supernatant was subjected to Western blot analysis for the Prdx I protein. Prdx IV was used as a loading
control. (E) The NB4 cells were treated with H7 for different times, and the intracellular ROS were evaluated by DCFDA staining. Each
experiment was repeated at least three times.
www.impactjournals.com/oncotarget

3875

Oncotarget

exerts dose- and time-dependent growth inhibition effect on
NB4 cells (Figure 3A). At 4 μM, H7 significantly inhibited
NB4 cell growth without obvious loss of cell viability.
Thus, we selected this H7 concentration in subsequent
experiments. The NB4 cells were treated with H7 for 24, 48,
and 72 h, and then cell differentiation was monitored. H7
treatment increased the percentages of CD11b- and CD14positive cells (Figure 3B, 3C); morphologically, H7 also
reduced the nuclei/cytoplasm ratio, indicating monocyte
differentiation of NB4 cells (Figure 3D).

Figure  S2B). These data suggest that Prdx I plays an
essential role in H7-induced cell differentiation.

H7 induces cell differentiation of non-APL
leukemia cell lines and primary cells
To investigate whether the differentiation-inducing
effect of H7 is limited to NB4 cells, we investigated
the leukemia cell lines U937 and HL60, the primary
leukemia cells, and the normal cord blood or bone
marrow mononuclear cells (CBMNCs or BMMNCs).
U937, HL60, and NB4 cells expressed high protein
level of Prdx I. Varied expression levels of Prdx I were
observed in primary leukemia cells. In addition, Prdx I
was lowly expressed in normal CBMNCs and BMMNCs
(Figure 5A). H7 treatment also induced cell differentiation
in U937 (Figure 5B, 5C, Supplementary Figure S3A), in
HL60 (Figure  5D, 5E, Supplementary Figure  S3B), in
some primary leukemia cells (Figure 5F, 5G, Table 1,
Supplementary Figure S3C, 3D, 3E), and slightly in
CBMNCs and BMMNCs (Table  1, Supplementary
Figure S3F, 3G), as shown by the increased CD11b and
CD14 expression and/or by the morphological changes in
cells. These data suggest that the differentiation-inducing
effect of H7 is not limited to APL cells.

Prdx I is essential in H7-induced leukemia-cell
differentiation
To further confirm the role of Prdx I in H7-induced
cell differentiation, Prdx I was knocked down (Figure 4A,
NB4shPrdx I) or overexpressed in NB4 cells (Figure  4C,
NB4Prdx I), and nonspecific shRNA- (NB4shNC) or control
vector-transfected cells (NB4vector) were used as negative
controls, respectively. Prdx I knockdown induced cell
differentiation in NB4 cells, whereas H7 treatment further
increased the percentages of CD11b/CD14-positive cells
(Figure  4B, Supplementary Figure  S2A). By contrast,
Prdx I overexpression in NB4 cells partially blocked the
differentiation effect of H7 (Figure  4D, Supplementary

Figure 3: H7 induces partial differentiation of NB4 cells. (A) The NB4 cells were treated with different H7 concentrations for

24 and 48 h. Cell proliferation was determined by trypan blue exclusion assay. (B–C) The NB4 cells were treated with H7 for 1, 2, and
3 days, and the CD11b and CD14 expression levels were determined by FACS. The representative histogram and percentages of CD11b and
CD14 are shown in (B) and (C), respectively. All values represent the means ± S.D. of three independent experiments. *p < 0.05 compared
with the control group. (D) The NB4 cells were treated with H7 for 3 days, and cell morphology was examined by Wright’s staining and
light microscopy (100 ×). Each experiment was repeated at least three times.
www.impactjournals.com/oncotarget

3876

Oncotarget

H7 induces differentiation through activation of
the ROS-Erk1/2-C/EBPβ pathway

and CD14 upregulation (Figure 6D). These data suggest
that Erk1/2 activation is involved in H7-induced cell
differentiation.
C/EBPβ is also speculated to drive immature cells to
become granulocytes and monocytes and has been shown
as an important downstream target of Erk1/2 [25]; thus,
we determined the C/EBPβ expression upon H7 treatment.
H7 treatment increased C/EBPβ expression, which was
abrogated by co-treatment of NAC (Figure  6B). The
Erk1/2 inhibitor PD98059 also inhibited the H7-induced
C/EBPβ upregulation (Figure 6C). Moreover, knockdown
of C/EBPβ (Figure 6E) abrogated the H7-induced CD11b
and CD14 upregulation (Figure 6F). These data suggest
that H7-induced cell differentiation is mediated through
the ROS-Erk1/2-C/EBPβ axis.

Given that the Prdx I inhibitor adenanthin induces
leukemia-cell differentiation by increasing ROS level,
we hypothesized that H7 induces cell differentiation
in a similar manner. To determine the role of ROS in
H7-induced cell differentiation, we treated the NB4 cells with
H7 in the presence or absence of N-acetyl cysteine (NAC),
a ROS scavenger. NAC treatment significantly inhibited
H7-induced CD11b and CD14 upregulation (Figure 6A).
These data suggest that H7 induces leukemia-cell
differentiation in a ROS-dependent manner.
Furthermore, activation of the AKT or MAPK
signaling pathway has been implicated in ROS-mediated
cell differentiation [23–24]. H7 treatment indeed
activated AKT, as evidenced by the increased AKTSer473
phosphorylation (Figure  6B). However, knockdown of
AKT expression by shRNA did not affect H7-induced
cell differentiation, indicating that AKT activation
is not involved in H7-induced cell differentiation
(Supplementary Figure S4). Given that Erk1/2 activation
is involved in adenanthin-induced differentiation, we
then evaluated the possible role of Erk1/2. H7 treatment
activated Erk1/2 (Figure 6B). By contrast, co-treatment
of H7 with the Erk1/2 inhibitor PD98058 inhibited the
H7-induced Erk1/2 activation (Figure 6C) and the CD11b

H7 induces leukemia-cell differentiation in vivo
Given that H7 induces cell differentiation in vitro,
we then attempted to determine the effect of H7 in vivo
in our APL mouse model. Compared with the vehicletreated leukemic mice, the intraperitoneal injection of H7
at 10 and 20 mg/kg increased the terminally differentiated
cells in the bone marrow (BM) and peripheral blood (PB),
as reflected by the increase in maturating myeloid cells
showing differentiation-related morphologic features,
such as condensed chromatin with indented, distorted, and

Figure 4: Knockdown or overexpression of Prdx I increases or decreases H7-induced cell differentiation. (A) The NB4

cells were transfected with non-specific shRNA (NB4shNC) or Prdx I specific shRNA (NB4shPrdx I). The indicated proteins were examined by
Western blot. (B) The NB4shNC and NB4shPrdx I cells were treated with H7 for 3 days, and the expression of CD11b, CD14 were determined
by FACS. All values represent the means ± S.D. of three independent experiments. *p < 0.05 compared with the control group. (C) The
NB4 cells were transfected with the vector (NB4NC) or Prdx I plasmid (NB4Prdx I). The indicated proteins were examined by Western blot.
(D) The NB4NC and NB4Prdx I cells were treated with H7 for 3 days, and the expression of CD11b and CD14 were determined by FACS.
All values represent the means ± S.D. of three independent experiments. *p < 0.05 compared with the control group.
www.impactjournals.com/oncotarget

3877

Oncotarget

horse-shoe- or donut-shaped nuclei (Figure 7A). Moreover,
we measured the mouse granulocytic differentiationrelated antigens Gr-1 and Mac-1 after gating for myeloid
cells by FSC and SSC on flow cytometry. The results
showed that in these myeloid cells, the percentages of
Gr-1+ and Mac-1+ cells were much higher in the BM of the
H7-treated leukemic mice than those of the vehicle-treated
leukemic mice (Figure 7B and 7C). These data indicate
that H7 induces leukemia-cell differentiation in vivo.

enzymes, such as catalase, glutathione peroxidase 1, and
Prdxs. We recently proposed that targeting the Prdx/ROS
axis is a potential novel strategy in inducing leukemia-cell
differentiation [20]. However, this hypothesis has not yet
been confirmed.
To validate this hypothesis, we first attempted
to identify the novel Prdx I inhibitor. We demonstrated
that H7 is a novel Prdx I inhibitor, and this finding is
supported by several lines of evidence: (A) H7 inhibits
Prdx I activity in vitro. Moreover, our SPR analysis
showed that H7 rapidly associated and disassociated
with Prdx I, indicating their non-covalent bonding. The
docking study also showed that H7 stably interacted
with Prdx I through four hydrogen bonds. (B) H7 binds
to Prdx I in cells. Compared with other methods used in
confirming the interaction of small molecular compounds
with proteins, CETSA can be performed more easily and
can directly measure whether a drug molecule reached
its targets in cells and animal models [27]. Using this
method, we demonstrated that H7 indeed binds to Prdx
I in a biologically relevant circumstance. However, H7
could not interact with the four other two-cystein Prdxs
(Prdxs II–V), indicating that H7 is relatively selective
to Prdx I. The interaction of H7 with Prdx I is further

DISCUSSION
This study found H7 as a novel Prdx I-inhibiting
compound and demonstrated that H7 could induce
leukemia-cell differentiation. These results have validated
that Prdx I is a potential target in inducing leukemia-cell
differentiation.
Since the discovery of ROS, the primary focus
has been directed to the oxidative damage of biological
macromolecules, including proteins, DNA, and lipids.
However, accumulating evidence has suggested that
changing the cellular ROS level is useful in altering the
cell differentiation status [6, 26]. The homeostasis of redox
reactions in cells is controlled primarily by antioxidant

Figure 5: H7 induces monocyte differentiation in U937, HL60, and primary leukemia cells. (A) Prdx I expression in

different cell lines and primary cells were determined by Western blot. (B–F) The indicated cells were treated with H7 for 3 days, and cell
morphology was examined by Wright’s staining and light microscopy (100 ×) (B, D, F, day 3). The cell surface markers CD11b and CD14
were detected by FACS, and the percentages of CD11b and CD14 are shown in (C, E, and G). All values represent the means ± S.D. of three
independent experiments. *p < 0.05 compared with the control group.
www.impactjournals.com/oncotarget

3878

Oncotarget

Table 1: Effect of H7 on differentiation of primary blood cells
CD11b

CD14

DMSO

H7

DMSO

H7

Pt1

12.62 ± 1.45

38.69 ± 1.37*

8.54 ± 0.57

29.57 ± 1.45*

Pt3

8.82 ± 0.20

35.48 ± 0.82*

10.64 ± 0.17

40.78 ± 0.39*

Pt5

7.63 ± 0.16

39.08 ± 0.13*

11.4 ± 3.91

17.23 ± 1.72

CB3

31.56 ± 0.52

43.76 ± 1.87

30.90 ± 0.23

48.15 ± 0.24*

BM1

38.56 ± 0.18

38.90 ± 0.17

23.31 ± 0.56

23.82 ± 0.92

Note: Mononuclear cells from bone marrow or cord blood cells were treated with H7 for 3 days. The percentages of CD11b
and CD14 were evaluted by FACS. All values represent means ± S.D. of three independent experiments. *p < 0.05 compared
with the DMSO-treated cells.
demonstrated by drug affinity responsive target stability
(DARTS) assay, which is another established and valid
methodology for identifying and studying protein–ligand
interactions. Indeed, H7 can protect Prdx I from proteaseinduced degradation, indicating that H7 may bind to Prdx I
(Supplementary Figure S1). (C) Consistent with its Prdx I
inhibition activity, H7 treatment increases ROS level in
cells.
Using H7 as a chemical probe, we further
demonstrated that targeting the Prdx I indeed induced
leukemia-cell differentiation. Manipulating the protein
level by overexpression or knockdown experiments could
decrease or increase H7-induced cell differentiation,
further demonstrating that Prdx I is critical in H7-induced
cell differentiation. Consistent with our previous report [20],
inducing cell differentiation by targeting Prdx I is not
limited to NB4 cells. Other non-APL cells and primary
leukemia blast cells could also be induced by H7 to
differentiate. In addition, H7 treatment could induce cell
differentiation in leukemic mice, although H7 failed to
prolong the survival of leukemic mice possibly because
of its toxicity. Injection of H7 at 20 mg/kg through the
tail vein caused mummification necrosis of the tail. By
contrast, the mice were more tolerant to intraperitoneal
injection of H7, although long-term treatment at 20 mg/kg
still resulted in early death of the leukemic mice
(data  not  shown). Decreasing the concentration of H7
to 10 mg/kg will not only reduce its toxicity but also its
efficacy. Therefore, optimizing H7 to reduce its toxicity is
required. Taken together, these results further confirmed
that targeting Prdx I could induce differentiation in APL
and non-APL cells.
We previously demonstrated that the Prdx I-ROS axis
is vital to the adenanthin-induced cell differentiation [20].
Consistent with this finding, NAC, a blocker of ROS,
also inhibited H7-induced leukemia-cell differentiation.
This observation suggests that H7 induces leukemia-cell
differentiation through the Prdx I-ROS axis. Moreover,
the activation of AKT or MAPK signaling pathway has
been implicated in ROS-mediated cell differentiation
[23–24]. H7 treatment activated AKT and Erk1/2.
www.impactjournals.com/oncotarget

However, inhibition of Erk1/2 but not of Akt could
inhibit H7-induced cell differentiation, indicating that
Erk 1/2 activation is involved in the H7-induced cell
differentiation. C/EBPβ is also a key transcription factor
regulating monocytic gene expression. Several reports and
ours have shown that C/EBPβ is an important downstream
molecule of Erk1/2 [28–29]. We then investigated the
possible role of C/EBPβ in H7-induced leukemia-cell
differentiation. As expected, NAC blocked the H7-induced
C/EBPβ upregulation in leukemia cells. In addition,
silencing of the C/EBPβ protein could weaken the ability
of H7 to induce leukemia-cell differentiation. Thus, we
proposed that H7 induces leukemia-cell differentiation
through the Prdx I-ROS-Erk1/2-C/EBPβ axis.
In conclusion, our findings verified in principle
that Prdx I is a novel target for inducing leukemia-cell
differentiation. Moreover, H7 is a novel lead compound
for optimizing Prdx I inhibition.

MATERIALS AND METHODS
Virtual screening
Virtual screening and docking were performed using
Glide version 5.5 (Schrodinger Suite 2009) with default
docking parameter settings. The Prdx I structure was
retrieved from the Protein Data Bank (PDB entry: 1QQ2).
Hydrogen atoms and charges were added during a brief
relaxation, which was performed using the “Protein
Preparation” module in Maestro and executing the
“preparation and refinement” option; the restrained partial
minimization was terminated when the root-mean-square
deviation reached a maximum value of 0.3 Å to relieve
the steric clashes of amino acid residues located within
14 Å from the catalytic thiolate of Cys52; these amino
acid residues were defined as part of the binding site for
docking studies. All crystallographic water molecules
were removed from the coordinate set. Moreover, the
compound library for screening was obtained from SPECS
company [http://www.specs.net/ (October 1, 2013)]. All
180,000 compounds were desalted, neutralized, and
3879

Oncotarget

Figure 6: H7 induces monocyte differentiation via ROS-C/EBPβ axis in NB4 cells. (A–B) The NB4 cells were treated with

H7 in the presence or absence of NAC for 3 days, and the expression of the cell surface markers CD11b and CD14 was detected by FACS.
All values represent the means ± S.D. of three independent experiments. *p < 0.05 compared with the single treatment (A); the indicated
proteins were examined by Western blot (B). (C–D) The NB4 cells were treated with H7 for 3 days in the presence or absence of PD98059,
and the expression levels of the cell surface marker CD11b and CD14 were detected by FACS. All values represent the means ± S.D. of
three independent experiments. *p < 0.05 compared with the H7 treatment (D); the indicated proteins were examined by Western blot (C).
(E–F) The C/EBPβ knockdown NB4 cells (NB4shC/EBPβ) and the control NB4 cells (NB4shNC) were treated with H7 for 3 days, and the
expression of the indicated proteins were detected by Western blot (E); the expression levels of the CD11b+ and CD14+ were detected by
FACS. All values represent the means ± S.D. of three independent experiments. *p < 0.05 compared with the H7-treated NB4shNC cells (F).

Figure 7: H7 induces leukemia-cell differentiation in vivo. APL leukemic mice were treated with vehicle and H7 (10 mg/kg,

20 mg/kg, introperitoneal) daily for 5 consecutive days. When the first vehicle-treated leukemic mice were moribund, all mice were killed
and analyzed. The cytologic analysis by Wright’s staining of the peripheral blood (PB) and bone marrow (BM) are shown in (A) Scale bar,
20 µm. The expression levels of Gr-1+ and Mac-1+ were detected by FACS. The representative images are shown in (B) and the percentages
of Gr-1+ and Mac-1+ are shown in (C). All values represent the means ± S.D. of three independent experiments. *p < 0.05 compared with
the vehicle-treated mice cells (C).
www.impactjournals.com/oncotarget

3880

Oncotarget

parameterized using the OPLS 2005 force field. The
tautomers and ionization states expected to occur at
5.0–9.0 pH range were generated using the “ionize”
module. During docking, the standard-precision (SP) and
extra-precision (XP) dockings were adopted to generate
the minimized pose, and the Glide scoring function
(G-Score) was used in selecting the final pose exhibiting
the lowest energy conformation for each ligand [30].
Thirty-eight compounds from the top 100 compound
based on both the SP and XP scores were purchased and
dissolved in DMSO for biological testing.

for 20 min at 4°C to separate the soluble fractions from the
precipitates. The supernatants were transferred into new
microtubes and then analyzed by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) followed
by Western blot analysis.

DARTS
DARTS is a general methodology for identifying
and studying protein–ligand interactions [31] and was
performed to investigate the H7–Prdx I interaction.
Purified Prdx I protein were incubated with drugs or
vehicle at room temperature for 50 min, and the above
mixture was digested by pronase (10 mg/ml stock
solutions in water-aliquots stored at −20°C) at appropriate
ratio dissolved in TNC buffer (50 mM Tris-HCl pH
8.0, 50 mM NaCl, and 10 mM CaCl2) for 30 min. The
reaction was stopped by adding concentrated SDS-PAGE
loading buffer to final 1×, and then mixed well and boiled
immediately. The samples were subjected to Western blot.

Prdx I activity assay
Human Prdx I was cloned into pET28a vector
containing a His6 tag sequence at the N-terminal region.
The proteins were expressed in the Escherichia coli strain
BL21 and then purified. The Prdx I peroxidase activity
was detected by a standard Trx-Trx reductase-NADPHcoupled spectrophotometric assay as described previously
[20].

Cell culture and agents

SPR assay

The BM samples were collected from newly
diagnosed AML patients at the Tongren Hospital and
Shanghai  First  People’s  Hospital, which are affiliated
to Shanghai Jiaotong University School of Medicine
(SJTU-SM). Informed consent was obtained from
all patients and all manipulations were approved by
the Medical Science Ethics Committee of SJTU-SM.
The patients were diagnosed according to the FrenchAmerican-British classification. Patient (Pt) 1 is M3 type,
Pt 2–4 and 6 are M1 type, Pt 5 is M5 type. Normal cord
blood (CB) or bone marrow (BM) samples were collected
from healthy volunteers. In addition, the mononuclear
cells were aspirated by Ficoll–Paque liquid. The APL cell
line NB4 was obtained from Dr. Michel Lanotte (Hospital
Saint Louis, Paris, France), whereas the human monocytic
cell line U937 and the human myelomonocytic leukemia
cell line HL60 were obtained from the American Type
Culture Collection (Manassas, VA). The cells were grown
in RPMI-1640 (Bio-Whittaker Europe, Verviers, Belgium)
supplemented with 10% fetal calf serum (EuroClone, Life
Science Division, Milan, Italy) at 37°C in a humidified
atmosphere of 5% CO2.

The SPR experiments were performed on Biacore
T200 (GE Healthcare). Full-length human Prdx I was
immobilized on a CM5 chip (GE Healthcare) aiming at 500
response units using amine coupling chemistry. Compound
binding with Prdx I was analyzed in a single-cycle
kinetic analysis at 0.39–25 mM H7 concentration using
HBS-P buffer (10 mM HEPES, pH 7.4, 150 mM sodium
chloride (NaCl), 0.05% P20) at a flow rate of 30 µl/min
at 37°C. Biacore T200 Evaluation Software 1.0
(GE Healthcare) was used in data analysis.

CETSA
CETSA was performed according to the method
described [27]. NB4 cells were harvested and washed with
PBS. The cells were diluted in PBS supplemented with
complete protease inhibitor cocktail. The cell suspensions
were freeze-thawed three times using liquid nitrogen, and
the soluble fraction (lysate) was separated from the cell
debris by centrifugation at 20,000 g for 20 min at 4°C.
The cell lysates were subsequently diluted with PBS and
divided into two aliquots; one aliquot was treated with
DMSO and the other with H7 diluent. After 10–30 min
incubation at room temperature, the respective lysates
were divided into smaller (50  μL) aliquots and then
heated individually at different temperatures for 3 min
(Veriti Thermal Cycler, Applied Biosystems/Life
Technologies) followed by cooling for 3 min at room
temperature. The appropriate temperatures were
determined in preliminary CETSA experiments (data not
shown). The heated lysates were centrifuged at 20,000 g

www.impactjournals.com/oncotarget

Cell differentiation assay
The morphological features of the cells were
examined by microscopy after Wright’s staining (BASO
Diagnostic Inc., Guangdong, China) and the cell surface
differentiation antigens CD11b and CD14 were measured
using fluorescein isothiocyanate- or phycoerythrin-labeled
antibodies with isotype controls (Beckman-Coulter,
Miami, FL) by flow cytometry.

3881

Oncotarget

Detection of intracellular ROS

treated with vehicle (15% Cremophor EL, 15%
Propanediol, and 60% PBS) or H7. Cytological and
histological analyses were also performed. The Gr-1+/
Mac-1+ cells in BM were determined by FACS. Animal
handling was approved by the Committee for Humane
Treatment of Animals of SJTU-SM.

The oxidation-sensitive fluorescent probe dye
2′, 7′-dichlorodihydrofluorescein diacetate (DCF-DA,
Invitrogen Molecular Probes, Eugene, OR) was used
in measuring the intracellular ROS. DCF-DA is
deacetylated intracellularly by nonspecific esterases
and is further oxidized by cellular peroxides to the
fluorescent compound 2′, 7′-dichlorofluorescein. Briefly,
the cells treated with or without H7 were washed with
phosphate buffered saline (PBS) and then incubated
with 20 μM DCF-DA at 37°C for 30 min according to
the manufacturer’s instructions. The fluorescence signals
were detected by a FACStar Flow Cytometer (Beckman
Coulter). For each sample, 5,000 or 10,000 events were
collected. In addition, the H2O2 levels were expressed in
terms of mean fluorescence intensity.

Statistical analysis
Student’s t-test was used in evaluating the difference
between two treatments. A p value of less than 0.05 was
considered statistically significant.

ACKNOWLEDGMENTS AND FUNDING
This work was supported in part by the grants from the
National Basic Research Program of China (973 Program)
(No. 2015CB910403 and 2013CB910903), National
Natural Science Foundation of China (91313303, 81272886,
81300404, 81570118, 31100980, and 31300679), Science
and Technology Committee of Shanghai (11JC1406500,
15401901800, 13431900501, and 13ZR1456900), and
Shanghai Talent Development Project of Shanghai Human
Resource and Social Security Bureau.

RNA interference and transfection
Pairs of complementary oligonucleotides against
AKT (5′-GTGGTCATGTACGAGATGA-3′), C/EBPβ [20],
and non-target control shRNA were synthesized by
Sangon Biotech (Shanghai), annealed, and ligated into the
PSIREN-RetroQ Vector (Clontech Laboratories). These
shRNA-carrying retroviruses, which were produced in
293T cells, were used to infect the NB4 cells.

Abbreviations
Prdx I, peroxiredoxin I; ATRA, all trans-retinoic acid;
ROS, reactive oxygen species; NAC, N-acetyl cysteine;
APL, acute promyelocytic leukemia; PBS, phosphate
buffered saline; PDB, Protein Data Bank; RMSD, rootmean-square deviation; SP, standard-precision; XP, extraprecision; G-Score, Glide scoring function; CETSA, Cellular
Thermal Shift Assay; GPx, glutathione peroxidase 1.

Western blot
Equal volumes of cell lysates were loaded onto
10% SDS–polyacrylamide gel, electrophoresed, and
then transferred into ECL-nitrocellulose membranes
(Amersham, Buckinghamshire, UK). The membranes
were stained with 0.2% Ponceau S red to ensure equal
protein loading. After blocking with 5% nonfat milk in
Tris-buffered saline, the membranes were incubated with
the polyclonal antibodies against Prdxs I–V, C/EBPa,
and C/EBPβ (Santa Cruz Biotechnology, Santa Cruz,
CA) overnight at 4°C followed by incubation with
horseradish peroxidase-linked secondary antibody (cell
signaling) for 1 h at room temperature. Detection was
performed by SuperSignal West Pico Chemiluminescent
Substrate kit (Pierce, Rockford, IL) according to
manufacturer’s instruction. β-actin (Merck, Darmstadt,
Germany) was used as an internal control. Signal
intensity of proteins was normalized against β-actin
using Quantity One (Bio-Rad).

CONFLICTS OF INTEREST
The authors declare no conflicts of interest.

REFERENCES
1.	

2.	 Hughes PJ, Marcinkowska E, Gocek E, Studzinski GP,
Brown G. Vitamin D3-driven signals for myeloid cell
differentiation—implications for differentiation therapy.
Leuk Res. 2010; 34:553–565.
3.	 Marchwicka A, Cebrat M, Sampath P, Sniezewski L,
Marcinkowska E. Perspectives of differentiation therapies of
acute myeloid leukemia: the search for the molecular basis
of patients' variable responses to 1,25-dihydroxyvitamin d
and vitamin d analogs. Front Oncol. 2014; 4:125.

Mouse APL model
The leukemia-cells isolated from the spleens of
leukemic hMRP8-PML-RARa transgenic mice were
intravenously injected into the 6- to 8-week-old female
FVB/N mice following sublethal irradiation. Three days
after transplantation, the mice were intraperitoneally
www.impactjournals.com/oncotarget

Gocek E, Marcinkowska E. Differentiation therapy of acute
myeloid leukemia. Cancers (Basel). 2011; 3:2402–2420.

4.	 Trump DL, Deeb KK, Johnson CS. Vitamin D:
considerations in the continued development as an agent
for cancer prevention and therapy. Cancer J. 2010; 16:1–9.
3882

Oncotarget

5.	

Hole PS, Darley RL, Tonks A. Do reactive oxygen species play
a role in myeloid leukemias? Blood. 2011; 117:5816–5826.

20.	 Liu CX, Yin QQ, Zhou HC, Wu YL, Pu JX, Xia L, Liu W,
Huang X, Jiang T, Wu MX, He LC, Zhao YX, Wang XL,
et al. Adenanthin targets peroxiredoxin I and II to induce
differentiation of leukemic cells. Nat Chem Biol. 2012;
8:486–493.

6.	 Yamamoto T, Sakaguchi N, Hachiya M, Nakayama F,
Yamakawa M, Akashi M. Role of catalase in monocytic
differentiation of U937 cells by TPA: hydrogen peroxide as
a second messenger. Leukemia. 2009; 23:761–769.

21.	 Liu CX, Zhou HC, Yin QQ, Wu YL, Chen GQ. Targeting
peroxiredoxins against leukemia. Exp Cell Res. 2013;
319:170–176.

7.	 Irwin ME, Rivera-Del Valle N, Chandra J. Redox control
of leukemia: from molecular mechanisms to therapeutic
opportunities. Antioxid Redox Signal. 2013; 18:1349–1383.
8.	

22.	 Martinez Molina D, Jafari R, Ignatushchenko M, Seki T,
Larsson EA, Dan C, Sreekumar L, Cao Y, Nordlund P.
Monitoring drug target engagement in cells and tissues
using the cellular thermal shift assay. Science. 2013;
341:84–87.

Owusu-Ansah E, Banerjee U. Reactive oxygen species prime
Drosophila haematopoietic progenitors for differentiation.
Nature. 2009; 461:537–541.

9.	 Noh EK, Kim H, Park MJ, Baek JH, Park JH, Cha SJ,
Won  JH, Min YJ. Gefitinib enhances arsenic trioxide
(AS2O3)-induced differentiation of acute promyelocytic
leukemia cell line. Leuk Res. 2010; 34:1501–1505.

23.	 Wang R, Xia L, Gabrilove JL, Waxman S, Jing Y. Sorafenib
inhibition of Mcl-1 accelerates ATRA induced apoptosis
in differentiation responsive AML cells. Clin Cancer Res.
2015 Oct 12; PMID: 26459180.

10.	 Liu T, Men Q, Wu G, Yu C, Huang Z, Liu X, Li W. Tetrandrine
induces autophagy and differentiation by activating ROS and
Notch1 signaling in leukemia cells. Oncotarget. 2015. doi:
10.18632/oncotarget.3505.

24.	 Imran M, Park TJ, Lim IK. TIS21/BTG2/PC3 enhances
downregulation of c-Myc during differentiation of HL-60
cells by activating Erk1/2 and inhibiting Akt in response to
all-trans-retinoic acid. Eur J Cancer. 2012; 48:2474–2485.

11.	 Rhee SG, Woo HA. Multiple functions of peroxiredoxins:
peroxidases, sensors and regulators of the intracellular
messenger H(2)O(2), and protein chaperones. Antioxid
Redox Signal. 2011; 15:781–794.

25.	 Huber R, Pietsch D, Panterodt T, Brand K. Regulation of C/
EBPbeta and resulting functions in cells of the monocytic
lineage. Cell Signal. 2012; 24:1287–1296.
26.	 Ding Q, Jin T, Wang Z, Chen Y. Catalase potentiates retinoic
acid-induced THP-1 monocyte differentiation into macrophage
through inhibition of peroxisome proliferator-activated
receptor gamma. J Leukoc Biol. 2007; 81:1568–1576.

12.	 Ray PD, Huang BW, Tsuji Y. Reactive oxygen species
(ROS) homeostasis and redox regulation in cellular
signaling. Cell Signal. 2012; 24:981–990.
13.	 Park J, Lee S, Kang SW. 2-cys peroxiredoxins: emerging
hubs determining redox dependency of Mammalian
signaling networks. Int J Cell Biol. 2014; 2014:715867.

27.	 Jafari R, Almqvist H, Axelsson H, Ignatushchenko M,
Lundback T, Nordlund P, Martinez Molina D. The cellular
thermal shift assay for evaluating drug target interactions in
cells. Nat Protoc. 2014; 9:2100–2122.

14.	 Woo HA, Yim SH, Shin DH, Kang D, Yu DY, Rhee SG.
Inactivation of peroxiredoxin I by phosphorylation allows
localized H(2)O(2) accumulation for cell signaling. Cell.
2010; 140:517–528.

28.	 Wen CL, Teng CL, Chiang CH, Chang CC, Hwang WL,
Kuo CL, Hsu SL. Methanol extract of Antrodia cinnamomea
mycelia induces phenotypic and functional differentiation
of HL60 into monocyte-like cells via an ERK/CEBP-beta
signaling pathway. Phytomedicine. 2012; 19:424–435.

15.	 Demasi AP, Ceratti D, Furuse C, Cury P, Junqueira JL,
Araujo VC. Expression of peroxiredoxin I in plasma cells of
oral inflammatory diseases. Eur J Oral Sci. 2007; 115:334–337.

29.	 Ji Y, Lee HJ, Goodman C, Uskokovic M, Liby K, Sporn M,
Suh N. The synthetic triterpenoid CDDO-imidazolide
induces monocytic differentiation by activating the Smad
and ERK signaling pathways in HL60 leukemia cells. Mol
Cancer Ther. 2006; 5:1452–1458.

16.	Demasi AP, Magalhaes MH, Furuse C, Araujo NS,
Junqueira JL, Araujo VC. Peroxiredoxin I is differentially
expressed in multiple myelomas and in plasmablastic
lymphomas. Oral Dis. 2008; 14:741–746.
17.	 Chhipa RR, Lee KS, Onate S, Wu Y, Ip C. Prx1 enhances
androgen receptor function in prostate cancer cells by
increasing receptor affinity to dihydrotestosterone. Mol
Cancer Res. 2009; 7:1543–1552.

30.	 Huang Z, Mou L, Shen Q, Lu S, Li C, Liu X, Wang G, Li S,
Geng L, Liu Y, Wu J, Chen G, Zhang J. ASD v2.0: updated
content and novel features focusing on allosteric regulation.
Nucleic Acids Res. 2014; 42:D510–516.

18.	 Zhang B, Wang Y, Su Y. Peroxiredoxins, a novel target in
cancer radiotherapy. Cancer Lett. 2009; 286:154–160.

31.	 Lomenick B, Olsen RW, Huang J. Identification of direct
protein targets of small molecules. ACS Chem Biol. 2011;
6:34–46.

19.	 Riddell JR, Bshara W, Moser MT, Spernyak JA, Foster BA,
Gollnick SO. Peroxiredoxin 1 controls prostate cancer
growth through Toll-like receptor 4-dependent regulation
of tumor vasculature. Cancer Res. 2011; 71:1637–1646.

www.impactjournals.com/oncotarget

3883

Oncotarget

